|
Big or Small, FDA Wants to Hear About All Trial-Related AEs
Trial sponsors should notify the FDA about all adverse events brought to their attention by data monitoring committees (DMC), regardless of whether the safety issue is “serious” or not, according to an agency guidance.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives